Milestones. In the event that a Default Notice has been delivered by Abbott under this [Section 13.2], then unless and until the corresponding material breach has been cured by [[Surmodics:Organization]] or Abbott indicates that it no longer intends to terminate for material breach, then any obligation that Abbott may have to pay a Milestone Payment in respect of any Milestone achieved after delivery of such Default Notice shall be suspended unless and until it is determined, in accordance with [Section 13.2.1], that a material breach has not occurred. In the event that a termination for material breach occurs pursuant to this [Section 13.2], then Abbott’s obligation to pay such Milestone Payment(s) shall cease and such suspended Milestone Payment(s) shall no longer be due.

As additional consideration for Institute entering into this Agreement and diligently progressing the activities under the Research Collaboration in accordance with this Agreement, Atara has paid, or will pay to Institute the research milestone payments (each, a “Research Milestone Payment”) set forth in the table below for each Allogeneic CTL Product and/or Autologous CTL Product (as applicable pursuant to the table set forth below) to achieve the corresponding milestone (each, a “Research Milestone”), whether achieved by Institute, Atara or an Affiliate or sublicensee of Atara. The Party achieving such Research Milestone shall promptly notify the other Party in writing of the achievement of any such Research Milestone and Atara shall pay Institute in full the corresponding Research Milestone Payment within [ * ] of such achievement. For clarity, each Research Milestone Payment is payable once only for each Allogeneic CTL Product and once for each Autologous CTL Product, and each Research Milestone Payment is non-refundable, and is not an advance against royalties due to Institute or any other amounts due to Institute. The Parties acknowledge and agree that as of the Execution Date, Atara has paid the Research Milestone Payment for First Dosing in a Human Subject for a CTL Product Specifically Directed to EBV for a first Allogeneic CTL Product.

Milestones. In partial consideration of the rights granted by [[Surmodics:Organization]] to Abbott hereunder and subject to the terms and conditions set forth in this Agreement, within ​ of the occurrence of each milestone specified in [Section 1 of Schedule 7] (each, a “Milestone”), Abbott shall pay to [[Surmodics:Organization]] the corresponding amount specified for such Milestone, provided that such amount may be reduced by the operation of [Section 3 of Schedule 7] (such amount, as it may be reduced, a “Milestone Payment”). Each Milestone Payment shall be payable pursuant to this Section 7.2 only upon the first achievement of the applicable Milestone and no amounts shall be due for subsequent or repeated achievements of such Milestone. [[Surmodics:Organization]] shall use Commercially Reasonable Efforts to achieve each Milestone. The maximum aggregate amount payable by Abbott pursuant to this Section 7.2 for the Product is the amount set forth in [Section 2 of Schedule 7], provided that such amount may be reduced by the operation of [Section 3 of Schedule 7]. The milestone payments for each Option Product will be agreed by the Parties and set forth in the applicable Option Exercise Agreement.

Patent Milestones. Subject to the terms and conditions of this Agreement, INNOCOLL shall pay to [[DURECT:Organization]] ​ set forth in the following table .

Milestones. AstraZeneca shall make each of the substantive sales milestone payments indicated below to FibroGen Cayman when aggregate annual Net Sales of all

Milestones. Sunesis shall notify Millennium within ten (10) business days after the first achievement by a PDK Product of each of the following milestone events, and shall pay to Millennium the following amounts within thirty (30) days following the first achievement of each such event by Sunesis or its Affiliates or Sublicensees:

Milestones. In partial consideration for the rights, license and Option granted under this Agreement, Chondrial will pay to IU the following amounts upon the achievement of the following events:

Development Milestones. Catalyst agrees to pay Mosaic upon the occurrence of each of the following milestones ​ achieved by Catalyst or its Affiliates (but not, for clarity, by any Sublicensees) with respect to each Product, on a Product-by-Product and Indication-by-Indication basis, in accordance with this Section 10.1, provided, that at the time any such development milestone is achieved, that Catalyst is responsible for the development or regulatory activity with respect to such Product triggering such milestone. ​.

As additional consideration for Institute entering into this Agreement and diligently progressing the activities under the Research Collaboration in accordance with this Agreement, Atara has paid, or will pay to Institute the research milestone payments (each, a “Research Milestone Payment”) set forth in the table below for each Allogeneic CTL Product and/or Autologous CTL Product (as applicable pursuant to the table set forth below) to achieve the corresponding milestone (each, a “Research Milestone”), whether achieved by Institute, Atara or an Affiliate or sublicensee of Atara. The Party achieving such Research Milestone shall promptly notify the other Party in writing of the achievement of any such Research Milestone and Atara shall pay Institute in full the corresponding Research Milestone Payment within ​ of such achievement. For clarity, each Research Milestone Payment is payable once only for each Allogeneic CTL Product and once for each Autologous CTL Product, and each Research Milestone Payment is non-refundable, and is not an advance against royalties due to Institute or any other amounts due to Institute. The Parties acknowledge and agree that as of the Execution Date, Atara has paid the Research Milestone Payment for First Dosing in a Human Subject for a CTL Product Specifically Directed to EBV for a first Allogeneic CTL Product.

In partial consideration for the amendment and restatement of the Prior Agreement and the rights and licenses granted to [[EPIZYME:Organization]] hereunder, [[EPIZYME:Organization]] shall make the non-creditable milestone payments to EISAI that are set forth below in accordance with [Section 6.3.2] upon the first occurrence of the milestone events set forth below.